← FDA DRUG APPROVALS

FDA ANDA · ANDA215123

NINTEDANIB

Sponsor: EUGIA PHARMA SPECLTS

APPLICATION
ANDA215123
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
None (Tentative Approval)

Products

NINTEDANIBNone (Tentative Approval)
NINTEDANIB EQ 150MG BASE · CAPSULE · ORAL

Approval history

2026-02-04UNKNOWN · Original · standardTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →